1.
Journal of Sun Yat-sen University(Medical Sciences)
; (6): 925-930, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-998983
ABSTRACT
Crohn’s Disease (CD) is a destructive, relapsing and remitting chronic inflammatory bowel disease that usually progresses to irreversible intestinal structural and functional changes, such as intestinal lumen stenosis, fistula formation and perianal lesions, severely affecting the quality of life of patients. This review summarized the research progress on the mechanism, clinical application and safety of upadacitinib in the treatment of CD. Upadacitinib can increase the clinical remission and endoscopic response rates in patients with CD, improve the long-term outcome of CD patients and provide a new idea for the treatment of CD patients by using biological agents.